{"url_path":"/sec/rntx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1420565/0001193125-26-225352-index.html","accession_number":"0001193125-26-225352","cik":"0001420565","ticker":"RNTX","issuer_name":"Rein Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1420565/0001193125-26-225352-index.html","primary_entity_key":"0001420565","primary_entity_name":"Rein Therapeutics, Inc."},"word_count":571,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\nThe following exhibits are filed or furnished as part of this Quarterly Report on Form 10-Q.\n\n \n\nExhibit Number\n\n \n\nDescription\n\n \n\n \n\n \n\n3.1\n\n \n\n[Restated Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 11, 2021).](https://www.sec.gov/Archives/edgar/data/1420565/000156459021043417/alrn-ex31_544.htm)\n\n \n\n \n\n \n\n3.2\n\n \n\n[Certificate of Amendment of Restated Certificate of Incorporation of the Registrant, dated as of November 10, 2022 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 10, 2022).](https://www.sec.gov/Archives/edgar/data/1420565/000119312522282637/d379228dex31.htm)\n\n \n\n \n\n \n\n3.3\n\n \n\n[Certificate of Amendment of Restated Certificate of Incorporation of the Registrant, dated February 28, 2024 (incorporated by reference to Exhibit 3.3 of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 15, 2024).](https://www.sec.gov/Archives/edgar/data/1420565/000095017024044508/alrn-ex3_3.htm)\n\n \n\n \n\n \n\n3.4\n\n \n\n[Certificate of Amendment to Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 10, 2025).](https://www.sec.gov/Archives/edgar/data/1420565/000119312525004443/d898488dex31.htm)\n\n \n\n \n\n \n\n3.5\n\n \n\n[Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 10, 2025).](https://www.sec.gov/Archives/edgar/data/1420565/000119312525004443/d898488dex32.htm)\n\n \n\n \n\n \n\n4.1\n\n \n\n[Form of Unsecured Promissory Note (incorporated by reference from Company’s Current Report on Form 8-K filed on March 2, 2026)](https://www.sec.gov/Archives/edgar/data/1420565/000119312526084012/d121919dex101.htm)\n\n \n\n \n\n \n\n10.1\n\n \n\n[Form of Securities Purchase Agreement between the Registrant and the Investors (incorporated by reference from Company’s Current Report on Form 8-K filed on March 2, 2026)](https://www.sec.gov/Archives/edgar/data/1420565/000119312526084012/d121919dex101.htm)\n\n \n\n \n\n \n\n31.1\n\n \n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](rntx-ex31_1.htm)\n\n \n\n \n\n31.2\n\n \n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](rntx-ex31_2.htm)\n\n \n\n \n\n32.1\n\n \n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](rntx-ex32_1.htm)\n\n \n\n \n\n32.2\n\n \n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](rntx-ex32_2.htm)\n\n \n\n \n\n101.INS\n\n \n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.\n\n \n\n \n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n \n\n \n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n*\n\nIndicates management contract or compensatory plan.\n\n31\n\n \n\n+\n\nIn accordance with Item 601(b)(10)(iv) of Regulation S-K, certain information (indicated by “[**]”) has been excluded from this exhibit because it is both not material and private or confidential. A copy of the omitted portion will be furnished to the SEC upon request.\n\n#\n\nCertain schedules and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC.\n\n32\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\nRein Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\nDate: May 15, 2026\n\n \n\nBy:\n\n/s/ Brian Windsor, Ph.D.\n\nBrian Windsor, Ph.D.\n\nPresident and Chief Executive Officer\n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n \n\nDate: May 15, 2026\n\n \n\nBy:\n\n/s/ Timothy M. Cunningham\n\nTimothy M. Cunningham\n\nInterim Chief Financial Officer\n\n(Principal Financial Officer)\n\n \n\n33"}